ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · IEX Real-Time Price · USD
69.13
-0.56 (-0.80%)
Mar 28, 2024, 4:00 PM EDT - Market closed
ANI Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ANI Pharmaceuticals stock have an average target of 72.25, with a low estimate of 49 and a high estimate of 83. The average target predicts an increase of 4.51% from the current stock price of 69.13.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ANIP stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Capital One | Capital One | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Mar 15, 2024 |
Guggenheim | Guggenheim | Strong Buy Maintains $70 → $77 | Strong Buy | Maintains | $70 → $77 | +11.38% | Mar 5, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $73 → $83 | Strong Buy | Maintains | $73 → $83 | +20.06% | Mar 4, 2024 |
Truist Securities | Truist Securities | Strong Buy Maintains $72 → $80 | Strong Buy | Maintains | $72 → $80 | +15.72% | Mar 1, 2024 |
Truist Securities | Truist Securities | Strong Buy Maintains $70 → $72 | Strong Buy | Maintains | $70 → $72 | +4.15% | Feb 16, 2024 |
Financial Forecast
Revenue This Year
542.08M
from 486.82M
Increased by 11.35%
Revenue Next Year
581.71M
from 542.08M
Increased by 7.31%
EPS This Year
4.64
from 0.85
Increased by 445.40%
EPS Next Year
5.22
from 4.64
Increased by 12.60%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 562.2M | 614.3M | 659.2M | 627.3M | 657.8M |
Avg | 542.1M | 581.7M | 616.6M | 598.3M | 639.1M |
Low | 512.3M | 541.0M | 571.4M | 564.1M | 614.0M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 15.5% | 13.3% | 13.3% | 1.7% | 10.0% |
Avg | 11.4% | 7.3% | 6.0% | -3.0% | 6.8% |
Low | 5.2% | -0.2% | -1.8% | -8.5% | 2.6% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 5.23 | 5.70 | 6.20 | 6.59 | 7.22 |
Avg | 4.64 | 5.22 | 5.95 | 6.26 | 7.02 |
Low | 4.20 | 4.44 | 5.62 | 5.87 | 6.74 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 515.2% | 23.0% | 18.7% | 10.8% | 15.4% |
Avg | 445.4% | 12.6% | 14.1% | 5.1% | 12.1% |
Low | 394.6% | -4.2% | 7.6% | -1.4% | 7.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.